Orgenesis Inc. Working Capital

Working Capital of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.

Highlights and Quick Summary

  • Working Capital for the quarter ending September 29, 2021 was $22.8 Million (a -23.3% decrease compared to previous quarter)
  • Year-over-year quarterly Working Capital decreased by -32.6%
  • Annual Working Capital for 2020 was $33.8 Million (a -5.91% decrease from previous year)
  • Annual Working Capital for 2019 was $35.9 Million (a 173.07% increase from previous year)
  • Annual Working Capital for 2018 was $13.2 Million (a 0.0% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of Orgenesis Inc.

Most recent Working Capitalof ORGS including historical data for past 10 years.

Interactive Chart of Working Capital of Orgenesis Inc.

Orgenesis Inc. Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $22.78 $29.69 $35.78
2020 $33.79 $82.63 $84.55 $87.02 $33.79
2019 $35.91 $-3.59 $4.03 $2.18 $35.91
2018 $13.15 $9.7 $0.77 $-7.6 $13.15
2017 $-9.62 $-11.9 $-10.04 $3.1 $-9.62
2016 $-10.3 $-10.37 $-10.37 $-10.3
2015 $-8.27 $-8.27
2014 $-2.43 $-2.43
2013 $-0.89 $-0.89
2012 $-0.29 $-0.05
2011 $-0.29

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.